Cargando…

Graves’ disease and Graves’ orbitopathy following COVID-19

Detalles Bibliográficos
Autores principales:	Lanzolla, G., Marcocci, C., Marinò, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106371/ https://www.ncbi.nlm.nih.gov/pubmed/33964007 http://dx.doi.org/10.1007/s40618-021-01576-7

Ejemplares similares

Antioxidant Therapy in Graves’ Orbitopathy
por: Lanzolla, Giulia, et al.
Publicado: (2020)

Anti-nuclear autoantibodies in Graves’ disease and Graves’ orbitopathy
por: Lanzolla, G., et al.
Publicado: (2022)

Sirolimus as a second-line treatment for Graves’ orbitopathy
por: Lanzolla, G., et al.
Publicado: (2022)

Editorial: News in Graves’ orbitopathy: patients management and treatments
por: Lanzolla, Giulia, et al.
Publicado: (2023)

Surgical complications in orbital decompression for Graves' orbitopathy
por: Sellari-Franceschini, S., et al.
Publicado: (2016)

Selenium in the Treatment of Graves’ Hyperthyroidism and Eye Disease
por: Lanzolla, Giulia, et al.
Publicado: (2021)

Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement
por: Perros, P., et al.
Publicado: (2017)

Management of Graves’ hyperthyroidism and orbitopathy in time of COVID-19 pandemic
por: Bartalena, L., et al.
Publicado: (2020)

Beneficial effect of low-dose radioiodine ablation for Graves’ orbitopathy: results of a retrospective study
por: Lanzolla, Giulia, et al.
Publicado: (2021)

Graves' Orbitopathy
por: Hiromatsu, Yuji, et al.
Publicado: (2015)

The Role of the Microbiota in Graves’ Disease and Graves’ Orbitopathy
por: Hou, Jueyu, et al.
Publicado: (2021)

Asymmetric Graves’ Orbitopathy
por: Panagiotou, Grigorios, et al.
Publicado: (2020)

Effects of treatment modalities for Graves’ hyperthyroidism on Graves’ orbitopathy: a 2015 Italian Society of Endocrinology Consensus Statement
por: Bartalena, L., et al.
Publicado: (2015)

Cholesterol Serum Levels and Use of Statins in Graves' Orbitopathy: A New Starting Point for the Therapy
por: Lanzolla, Giulia, et al.
Publicado: (2020)

Orbital Signaling in Graves’ Orbitopathy
por: Draman, Mohd Shazli, et al.
Publicado: (2021)

Current Knowledge on Graves’ Orbitopathy
por: Gontarz-Nowak, Katarzyna, et al.
Publicado: (2020)

Reasons for revision surgery after orbital decompression for Graves’ orbitopathy
por: Sellari-Franceschini, Stefano, et al.
Publicado: (2008)

Thyrotropin receptor antibodies and Graves’ orbitopathy
por: Diana, T., et al.
Publicado: (2020)

Serum thyroglobulin is associated with orbitopathy in Graves’ disease
por: Khamisi, S., et al.
Publicado: (2021)

Graves′ orbitopathy: Management of difficult cases
por: Wiersinga, Wilmar M.
Publicado: (2012)

Comment on “factors associated with severity of orbitopathy in patients with Graves' disease
por: Nabi, Tauseef, et al.
Publicado: (2021)

Endoscopic orbital decompression for Graves’ orbitopathy
por: Lal, Priti, et al.
Publicado: (2013)

Current concepts regarding Graves’ orbitopathy
por: Bartalena, Luigi, et al.
Publicado: (2022)

Update on the surgical management of Graves’ orbitopathy
por: Baeg, Joonyoung, et al.
Publicado: (2023)

Significance of HLA in the development of Graves’ orbitopathy
por: Stasiak, Magdalena, et al.
Publicado: (2023)

Teprotumumab: a disease modifying treatment for graves’ orbitopathy
por: Ting, Michelle, et al.
Publicado: (2020)

Correction to: Thyrotropin receptor antibodies and Graves’ orbitopathy
por: Diana, T., et al.
Publicado: (2021)

Planning health care for patients with Graves’ orbitopathy
por: Sasim, Inna V., et al.
Publicado: (2008)

Factors associated with severity of orbitopathy in patients with Graves' disease
por: Nabi, Tauseef, et al.
Publicado: (2020)

Challenges and perspectives of selenium supplementation in Graves’ disease and orbitopathy
por: Bednarczuk, Tomasz, et al.
Publicado: (2019)

Significance of HLA in Graves’ disease and Graves’ orbitopathy in Asian and Caucasian populations – a systematic review
por: Stasiak, Magdalena, et al.
Publicado: (2023)

Mechanisms That Underly T Cell Immunity in Graves’ Orbitopathy
por: Fang, Sijie, et al.
Publicado: (2021)

Roles of four targets in the pathogenesis of graves' orbitopathy
por: Ren, Ziqiang, et al.
Publicado: (2023)

Atypical Asymmetric Presentation of Severe Graves’ Orbitopathy
por: Gupta, Priyanka, et al.
Publicado: (2023)

Evaluation of Quality of Life in the Brazilian Graves' Disease Population: Focus on Mild and Moderate Graves' Orbitopathy Patients
por: Villagelin, Danilo, et al.
Publicado: (2019)

Sex-specific risk factors associated with graves’ orbitopathy in Korean patients with newly diagnosed graves’ disease
por: Lee, Jooyoung, et al.
Publicado: (2023)

Adipocytokines in Graves’ orbitopathy and the effect of high-dose corticosteroids
por: Schovanek, Jan, et al.
Publicado: (2021)

IgG4 as a Biomarker in Graves' Orbitopathy
por: Olejarz, Michał, et al.
Publicado: (2021)

Acute Corneal Hydrops in Keratoconus Patients with Graves’ Orbitopathy
por: Dogan, Aysun Sanal, et al.
Publicado: (2021)

The Clinical Features of Graves' Orbitopathy with Elevated Intraocular Pressure
por: Fan, Shu-Xian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_c3leuivc4250d6m05jqrmem785